Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris McCabe

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Trials|May 11, 2011
Beta Agonist Lung Injury TrIal-2 (BALTI-2) trial protocol: a randomised, double-blind, placebo-controlled of intravenous infusion of salbutamol in the acute respiratory distress syndromeGavin D Perkins, Simon Gates, Sarah E Lamb, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 22, 2003
Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling StudiesMilton C Weinstein, Bernie O'Brien, John Hornberger, et al.
Applied Health Economics and Health Policy|February 10, 2006
Should patients have a greater role in valuing health states?John Brazier, Ron Akehurst, Alan Brennan, et al.
Health Economics|March 1, 2005
Probabilistic sensitivity analysis for NICE technology assessment: not an optional extraKarl Claxton, Mark Sculpher, Chris McCabe, et al.
Health Economics|December 21, 2005
Discounting and cost-effectiveness in NICE - stepping back to sort out a confusionKarl Claxton, Mark Sculpher, Anthony Culyer, et al.
Trials|May 21, 2021
Correction to: A novel preference-informed complementary trial (PICT) design for clinical trial research influenced by strong patient preferencesSamina Ali, Gareth Hopkin, Naveen Poonai, et al.
Trials|March 13, 2021
A novel preference-informed complementary trial (PICT) design for clinical trial research influenced by strong patient preferencesSamina Ali, Gareth Hopkin, Naveen Poonai, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|October 23, 2014
Sodium-23 magnetic resonance imaging has potential for improving penumbra detection but not for estimating stroke onset timeFriedrich Wetterling, Lindsay Gallagher, Jim Mullin, et al.
BMJ (Clinical Research Ed.)|March 8, 2003
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosisJim Chilcott, Chris McCabe, Paul Tappenden, et al.
Journal of Intensive Care|August 16, 2016
One-year resource utilisation, costs and quality of life in patients with acute respiratory distress syndrome (ARDS): secondary analysis of a randomised controlled trialJoachim Marti, Peter Hall, Patrick Hamilton, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Trials|May 11, 2011
Beta Agonist Lung Injury TrIal-2 (BALTI-2) trial protocol: a randomised, double-blind, placebo-controlled of intravenous infusion of salbutamol in the acute respiratory distress syndromeGavin D Perkins, Simon Gates, Sarah E Lamb, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 22, 2003
Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling StudiesMilton C Weinstein, Bernie O'Brien, John Hornberger, et al.
Applied Health Economics and Health Policy|February 10, 2006
Should patients have a greater role in valuing health states?John Brazier, Ron Akehurst, Alan Brennan, et al.
Health Economics|March 1, 2005
Probabilistic sensitivity analysis for NICE technology assessment: not an optional extraKarl Claxton, Mark Sculpher, Chris McCabe, et al.
Health Economics|December 21, 2005
Discounting and cost-effectiveness in NICE - stepping back to sort out a confusionKarl Claxton, Mark Sculpher, Anthony Culyer, et al.
Trials|May 21, 2021
Correction to: A novel preference-informed complementary trial (PICT) design for clinical trial research influenced by strong patient preferencesSamina Ali, Gareth Hopkin, Naveen Poonai, et al.
Trials|March 13, 2021
A novel preference-informed complementary trial (PICT) design for clinical trial research influenced by strong patient preferencesSamina Ali, Gareth Hopkin, Naveen Poonai, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|October 23, 2014
Sodium-23 magnetic resonance imaging has potential for improving penumbra detection but not for estimating stroke onset timeFriedrich Wetterling, Lindsay Gallagher, Jim Mullin, et al.
BMJ (Clinical Research Ed.)|March 8, 2003
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosisJim Chilcott, Chris McCabe, Paul Tappenden, et al.
Journal of Intensive Care|August 16, 2016
One-year resource utilisation, costs and quality of life in patients with acute respiratory distress syndrome (ARDS): secondary analysis of a randomised controlled trialJoachim Marti, Peter Hall, Patrick Hamilton, et al.
Pageof 4